Epigenetics in metabolic dysfunction-associated steatohepatitis

被引:0
|
作者
Zhang, Yanru [1 ,2 ]
Ding, Ruike [1 ,2 ]
Hu, Liangshuo [3 ]
Liu, Enqi [1 ,2 ]
Qu, Pengxiang [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Lab Anim Ctr, Hlth Sci Ctr, Xian 710061, Peoples R China
[2] Minist Educ China, Key Lab Environm & Genes Related Dis, Xian 710049, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
MASH; Epigenetics; Liver; DNA methylation; Histone modifications; Noncoding RNA; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; LIPID-METABOLISM; NONCODING RNAS; LIVER; EXPRESSION; DIET; HEPATOCYTES; FIBROSIS; INJURY;
D O I
10.1016/j.cellsig.2025.111684
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease involving genetics, environment, and lifestyle, with the potential to progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). Although the pathogenesis of MASH is not fully clear, increasing evidence has indicated that epigenetics plays an important role in the genesis and progression of MASH, during which, as drastic changes in metabolites, epigenetics undergo drastic changes. Roles of chromatin structure, chromatin accessibility, DNA methylation, histone modification, and non-coding RNAs were considered as bridges of pathogenic factors and MASH. In this review, the research progress on the epigenetics of MASH was summarized, and indepth research and therapeutic strategies based on epigenetics is expected to bring new hope to MASH patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Epigenetic regulation of thyroid hormone action in human metabolic dysfunction-associated steatohepatitis
    Naujack, Alison-Michelle
    Krause, Christin
    Britsemmer, Jan H.
    Taege, Natalie
    Mittag, Jens
    Kirchner, Henriette
    EUROPEAN THYROID JOURNAL, 2024, 13 (05)
  • [32] Inhibition of IRE-1α Alleviates Pyroptosis and Metabolic Dysfunction-Associated Steatohepatitis by Suppressing Gasdermin D
    Zeng, Xin
    Wu, Tian
    Xu, Qing
    Li, Lan
    Yuan, Yujia
    Zhu, Min
    Liu, Wen
    Fu, Fudong
    Wu, Zhenru
    Yao, Han
    Liao, Guangneng
    Lu, Yanrong
    Cheng, Jingqiu
    Liu, Jingping
    Shi, Yujun
    Chen, Younan
    LIVER INTERNATIONAL, 2025, 45 (02)
  • [33] Efficacy and safety of aldafermin for the treatment of metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis
    Khalil, Samira Mohamad
    de Souza, Matheus Henrique Gonsalves
    de Oliveira, Fabiana Dolovitsch
    Sato, Emmily Daiane Buarque de Santana
    Meine, Gilmara Coelho
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2025, 49 (05)
  • [34] Signaling through the nicotinic acetylcholine receptor in the liver protects against the development of metabolic dysfunction-associated steatohepatitis
    Jun, Heejin
    Liu, Shanshan
    Knights, Alexander J.
    Zhu, Kezhou
    Ma, Yingxu
    Gong, Jianke
    Lenhart, Ashley E.
    Peng, Xiaoling
    Huang, Yunying
    Ginder, Jared P.
    Downie, Christopher H.
    Ramos, Erika Thalia
    Kullander, Klas
    Kennedy, Robert T.
    Xu, X. Z. Shawn
    Wu, Jun
    PLOS BIOLOGY, 2024, 22 (07)
  • [35] Hepatic Amyloid Beta-42-Metabolizing Proteins in Liver Steatosis and Metabolic Dysfunction-Associated Steatohepatitis
    Gross, Simon
    Danielyan, Lusine
    Buechler, Christa
    Kubitza, Marion
    Klein, Kathrin
    Schwab, Matthias
    Melter, Michael
    Weiss, Thomas S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [36] USP13 ameliorates metabolic dysfunction-associated steatohepatitis through targeting PTEN
    Tang, Min
    Wei, Xiaohui
    Ma, Yunqin
    Tan, Yijiong
    Cao, Han
    Yao, Shuangshuang
    Wang, Jiaqi
    Yang, Hua
    Liu, Fang
    Peng, Yongde
    Fan, Nengguang
    LIFE SCIENCES, 2025, 360
  • [37] The Biological Clock of Liver Metabolism in Metabolic Dysfunction-Associated Steatohepatitis Progression to Hepatocellular Carcinoma
    Rajan, Pradeep Kumar
    Udoh, Utibe-Abasi S.
    Finley, Robert
    Pierre, Sandrine V.
    Sanabria, Juan
    BIOMEDICINES, 2024, 12 (09)
  • [38] FXR activation remodels hepatic and intestinal transcriptional landscapes in metabolic dysfunction-associated steatohepatitis
    Wen, Ying-quan
    Zou, Zi-yuan
    Zhao, Guan-guan
    Zhang, Meng-jiao
    Zhang, Yong-xin
    Wang, Gai-hong
    Shi, Jing-jing
    Wang, Yuan-yang
    Song, Ye-yu
    Wang, Hui-xia
    Chen, Ru-ye
    Zheng, Dong-xuan
    Duan, Xiao-qun
    Liu, Ya-meng
    Gonzalez, Frank J.
    Fan, Jian-gao
    Xie, Cen
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (11) : 2313 - 2327
  • [39] Hepatocellular RECK as a Critical Regulator of Metabolic Dysfunction-associated Steatohepatitis Development
    Dashek, Ryan J.
    Cunningham, Rory P.
    Taylor, Christopher L.
    Alessi, Isabella
    Diaz, Connor
    Meers, Grace M.
    Wheeler, Andrew A.
    Ibdah, Jamal A.
    Parks, Elizabeth J.
    Yoshida, Tadashi
    Chandrasekar, Bysani
    Rector, R. Scott
    CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2024, 18 (03):
  • [40] Alterations of valsartan pharmacokinetics in a rodent model of metabolic dysfunction-associated steatohepatitis
    Farrera, Dominique O.
    Alaaldin, Mina M.
    Lindberg, Paige
    Sample, Paxton A.
    Lenzen-Hammerel, Paige
    Lamadrid, Christopher S.
    Haymore, Ryan
    Wright, Stephen H.
    Cherrington, Nathan J.
    DRUG METABOLISM AND DISPOSITION, 2025, 53 (03)